C
ombinatorial antibody libraries celebrate their 20th anniversary this year. In 1989, the first functional antibodies were isolated from a combinatorial antibody library derived from an immunized mouse (1) . It was immediately evident that the technology would also lend itself to the generation of purely human monoclonal antibodies for medical use, which was not possible to achieve with the cell-based approaches for isolation of monoclonal antibodies used at the time. In these antibody libraries, mRNAs from B lymphocytes, coding for millions or even billions of the antibody heavy and light chains, are rescued by PCR technology and expressed as functional antibodies most often on phage that allow isolation of clones with particular characteristics, e.g., binding to a target molecule, cell type, or tissue (2, 3) . The libraries can be created from immune individuals, biased for clones against the immunogen, or be as diverse as possible, producing so-called naive libraries from which theoretically antibodies to any antigen may be isolated. The technology is so robust that isolation of the type of antibodies searched for most often is successful. Maybe because practical results are easy to achieve, but more importantly because the libraries have been too large to adequately analyze with available nucleotide sequencing methods, just how well these libraries mimic the immune system has not been possible to assess until now. In this issue of PNAS, Glanville et al. (4) provide the first in-depth characterization of a very large naive library of human IgM antibodies, derived from Ͼ650 individual donors and comprising Ͼ3 ϫ 10 10 members. Glanville et al. (4) have achieved this characterization by applying recent advances in nucleotide sequencing that allow robust one-run sequencing of the whole heavy and light chains and the chains combined (in single-chain variable fragment format). In addition, they have developed software enabling analysis of the large amount of data created by the new technologies. They present sequences of more than half a million heavy and light chains; previous attempts have resulted in hundreds of sequences at most.
The software used allowed the identification of the most variable portions of the variable Ig domains, the complementarity determining regions (CDRs), the germ-line genes from which the respective chains have been derived, and the contribution of somatic mutations to the variability of the antibodies in the library. The vast collection of new data show that CDR length (the most variable regions of the Ig chains on which the different binding characteristics of distinct antibodies are based) and germline contributions are reflected in their combinatorial library with extreme fidelity. In addition, the data put new emphasis on the contributions of mutations in the immune system for variability even in the CDR1 and CDR2 regions, previously considered to be less subject to variability by somatic mutations. After panning the library for antibodies binding to target molecules, the resulting population of clones had different VH germ-line distribution than the original library, as expected.
Taken together, the study clearly shows that the library is an exceptionally good mimic of the Ig repertoire, and that this can be achieved by technologies already used by hundreds of laboratories over the world (5, 6) .
Bias Caused by Host Cell Type?
Obviously, novel insights generate new questions. Glanville et al. (4) have analyzed the library on the nucleotide sequence level, but we do not know how well all clones are expressed and thus displayed on phage in the library. There have been several reports that the expression of Ig genes in prokaryotic hosts may introduce a bias, as evident in the isolation of distinct clones against a HIV-1 glycoprotein if the same library was displayed via a prokaryotic or eukaryotic system (Escherichia coli/phage vs. yeast) (7). Glanville et al. make a tentative conclusion that all clones are well represented because all VH germline genes occur among the isolated, antigen-specific antibodies, but a bias for some clones can be hidden in these results. By further use of large-scale sequencing technologies in experiments where the same library will be expressed in different display systems, further knowledge on this point may be obtained. In such investigations, both expression of libraries in cells per bacteria and via in vitro methods such as mRNA display etc., may be assessed (8) . Finding the most optimal antibody early in the discovery process is important because its quality and characteristics will have considerable scientific and financial implications for downstream processing, in particular if therapeutic use of the antibodies is the final goal. In addition, new additional structural information may be obtained, if different hosts give bias to certain structural elements in the immunologulin chains, and/or simply that a bias, if any, results from the primary sequence, codon use etc. (9) . The construction and use of future antibody libraries may thus be optimized based on these results.
Protective Immune Repertoire
Knowing now that combinatorial antibody libraries may be a very good mimic of antibodies existing in the organism, we may also address questions about the true variability in the antibody system in real life. The contributions by VDJ (for VH) and VJ (for VL) germ-line combinations, chain shuffling, imprecise joining, and somatic mutations have been estimated to provide a combinatorial potential of 10 11 to 10 14 , a considerable span. Future studies similar to that of The advances in recombinant Ig technologies in the 1980s and later laid the groundwork for the current surge in novel biological drugs. Among important discoveries were the possibility to express antibodies in recombinant form, to ''humanize'' mouse monoclonal antibodies by CDR grafting (10) , and to establish transgenic animals carrying human Ig loci (11) . For combinatorial antibody libraries, their inception was based on the detailed knowledge of the immunolglobulin combinatorial system and their nucleotide sequences, PCR technology, and the discovery that antibody fragments could be expressed in E. coli (1, (12) (13) (14) (15) . The first libraries created were so large that screening methods of the time did not suffice to explore their full potential. Only when phage display was applied to these libraries was it possible to isolate distinct clones of various specificities hidden in these ''haystacks'' (2, 16) . Over two decades, they have had substantial impact in studies of immune responses, vaccine design, catalysis, and theraputics, where one drug is already on the market [Humira (adalimumab)] and several more are in clinical trials, creating biotech industries and new avenues of discovery for existing pharmaceutical companies in the process. The advances presented by Glanville et al. (4) are likely to raise new interest in the foundations of these libraries, hopefully creating additional momentum for all of the areas where they are explored today.
